Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poliovirus vaccine SSI
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Poliovirus vaccine SSI is an inactivated poliovirus vaccine (IPV) developed by the Statens Serum Institut (SSI) for the prevention of poliomyelitis. It is a trivalent biologic containing formalin-inactivated poliovirus antigens of Type 1 (Brunhilde strain), Type 2 (MEF-1 strain), and Type 3 (Saukett strain). The development program includes a standard full-dose non-adjuvanted formulation (Poliovaccine SSI) and several reduced-dose formulations (1/3, 1/5, and 1/10 of the standard dose) adsorbed to an aluminium hydroxide adjuvant (IPV-Al SSI). These dose-sparing strategies are intended to improve the affordability and availability of IPV in global markets. A Phase 1 first-in-human trial conducted in Denmark evaluated the safety and immunogenicity of these formulations as boosters in adolescents, confirming they are safe and capable of inducing neutralizing antibody responses.
- Brand names
- Poliovaccine SSI
- Other names
- IPV Vaccine SSIinactivated poliovirus vaccine SSI
02
Targets
WPV3 (Poliovirus type 3 capsid protein)Poliovirus type 1 capsid protein
Beyond the preview
Go deeper on poliovirus vaccine SSI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poliovirus vaccine SSI.